Q3 2020

FreshLeaf Q3 Market Report Press Release

Australia’s Most Comprehensive Medicinal Cannabis Report: Q3 2020 Thursday 17 September 2020FreshLeaf Analytics is excited to release Australia’s most comprehensive medicinal cannabis Patient, Product and Pricing Analysis.Q3 was defined by the greatest drop in product price since early 2016 legalisation of medicinal cannabis products in Australia, as the market has grown 3x year on year...
Read More
Australian export laws amended to boost industry

FreshLeaf Analytics S3

FreshLeaf Analytics welcomes TGA interim decision on CBD down-scheduling September 9th 2020Therapeutic Goods Administration (TGA) sticks to their guns on initial proposal for over-the-Counter low-dose CBD but no smoking, vaping, topicals. Potential $200M market in Australia.FreshLeaf Analytics has welcomed the interim decision today by the Therapeutic Goods Administration (TGA) to make registered low-dose CBD products...
Read More
Epidioloex decision PBAC

Epidyolex decision PBAC

TGA Defers Decision to Pay for EpidyolexThe Pharmaceutical Benefits Advisory Committee (PBAC), the body that decides whether Australians can have certain medicines subsidised by the taxpayer,  has announced that it will not – for now – subsidize Epidyolex. Epidyolex is a medicinal cannabis product manufactured by UK cannabis giant GW Pharmaceuticals and containing the active...
Read More
July SASB numbers spike as Australia

July SASB numbers spike as Australia shoots for a more open minded future

July SASB numbers spike as Australia shoots for a more open minded future The Therapeutic Goods Administration (TGA) reported 5564 approvals this July for medicinal cannabis in Australia, a 20% increase from the month before. FreshLeaf Analytics notes that this brings Australia’s SASB approval total to over 56,000 to date since legislation in 2016.Tim Drury, Director...
Read More
TGA warns medical cannabis industry about advertising regulation breaches

TGA warns medical cannabis industry about advertising regulation breaches

TGA warns medical cannabis industry about advertising regulation breaches The Therapeutic Goods Administration (TGA), Australia’s health products regulator, has issued a stern warning to the medical cannabis industry that it will soon be ramping up its investigations into alleged breaches of the advertising regulations. This will dovetail with the TGA’s ongoing investigations into product quality...
Read More
Australian export laws amended to boost industry

Australian export laws amended to boost industry

The Export Control Legislation Amendment (Certification of Narcotic Exports) Bill 2020, which passed the Senate on June 17, will allow the Commonwealth Department of Agriculture, Water and the Environment to issue phytosanitary certificates for the export of medicinal cannabis and hemp products. This bill will remove an unintended regulatory barrier which has been hampering some...
Read More
CBD product

A CBD product might soon be available and subsidised on the Pharmaceutical Benefits Scheme

A CBD product might soon be available and subsidised on the Pharmaceutical Benefits Scheme   Families of children with severe drug-resistant epilepsy might soon be able to access a subsidised medicinal cannabis product in Australia.  In January 2020 the Department of Health, in their submission to the Senate Inquiry into barriers to patient access to...
Read More
NZ recreational cannabis bill released

NZ recreational cannabis bill released – prioritises social good over profits

NZ recreational cannabis bill released – prioritises social good over profits New Zealanders will go to the polls on September 19 to vote for their federal government as well as two contentious referenda: voluntary assisted dying and recreational cannabis. The full recreational cannabis bill is now published and the government has provided an accompanying plain-English...
Read More
CBD available for sale in pharmacies

Australian government proposes CBD be made available for retail sale

Australian government proposes CBD be made available for retail sale Today the Therapeutic Goods Administration released the Department of Health-initiated proposal to make low-dose CBD oil available for sale in pharmacies as a Schedule 3 drug. The proposed changes would allow the sale of pure CBD oil  (with 2% or less other cannabinoids) to adults...
Read More
Aust-Senate-website

Australian Senate Committee tables recommendations from inquiry into barriers to medical cannabis

Australian Senate Committee tables recommendations from inquiry into barriers to medical cannabis The Community Affairs and References Committee tabled their report today (25/3/20) on the inquiry into barriers to medical cannabis patient access in Australia.  FreshLeaf has covered this inquiry extensively and attended the public hearings, so if you’re interested in the recent history of...
Read More
1 2 3